IPSOS
Ipsos will not submit an offer for the acquisition of Kantar Media
Ipsos will not submit an offer for the acquisition of Kantar Media
Ipsos will not submit an offer for the acquisition of Kantar Media
Paris, December 5, 2024 – After careful review of a potential acquisition of Kantar Media, Ipsos has, at this time, decided not to submit a binding offer.
ABOUT IPSOS
Ipsos is one of the largest market research and polling companies globally, operating
in 90 markets and employing nearly 20,000 people.
Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 business solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.
“Game Changers” – our tagline – summarizes our ambition to help our 5,000 clients navigate with confidence our rapidly changing world.
Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120, Mid-60 indices, STOXX Europe 600 and is eligible for the Deferred Settlement Service (SRD).
ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP
www.ipsos.com
35 rue du Val de Marne
75 628 Paris, Cedex 13 France
Tel. +33 1 41 98 90 00
Attachment
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
dsm-firmenich2.6.2025 13:12:47 CEST | Press release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Novonesis (Novozymes A/S)2.6.2025 13:05:24 CEST | Press release
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance
Outlook Therapeutics, Inc.2.6.2025 13:00:00 CEST | Press release
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
Denodo Technologies Inc. (“Denodo”)2.6.2025 13:00:00 CEST | Press release
Denodo University Challenge Now Open: Data and AI for Real-World Impact
Nykredit Realkredit A/S2.6.2025 12:44:05 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom